Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Epizyme, Inc. (EPZM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update"
05/10/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update"
05/06/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results"
11/06/2020 8-K Quarterly results
Docs: "Epizyme Reports Business Progress and Third Quarter 2020 Financial Results"
08/04/2020 8-K Quarterly results
05/04/2020 8-K Quarterly results
10/30/2019 8-K Quarterly results
08/09/2019 8-K Quarterly results
05/06/2019 8-K Quarterly results
Docs: "Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected ...",
"Epizyme Provides Business Update and Reports First Quarter 2019 Financial Results"
11/02/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Epizyme Reports Third Quarter 2018 Financial Results and Tazemetostat Progress"
08/02/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : August 2, 2018 EPIZYME, INC. Delaware 001-35945 26-1349956 400 Technology Square, Cambridge, Massachusetts 02139 Registrant's telephone number, including area code: 229-5872",
"Epizyme Reports Second Quarter 2018 Financial Results and Provides Business Updates"
11/01/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : November 1, 2017 EPIZYME, INC. Delaware 001-35945 26-1349956 400 Technology Square, Cambridge, Massachusetts 02139 Registrant's telephone number, including area code: 229-5872",
"Epizyme Reports Third Quarter 2017 Operating Results and Company Updates"
08/04/2017 8-K Quarterly results
Docs: "Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress"
03/09/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/08/2016 8-K Form 8-K - Current report
05/09/2016 8-K Quarterly results
Docs: "Epizyme Announces First Quarter 2016 Financial Results and Provides Update on Execution Against Multi-Year Company Vision"
03/09/2016 8-K Form 8-K - Current report
11/09/2015 8-K Quarterly results
Docs: "Epizyme Announces Third Quarter 2015 Financial Results and Provides Corporate Update"
08/06/2015 8-K Quarterly results
Docs: "Consulting Agreement between the Company and Robert J. Gould, Ph.D.",
"Employment Offer Letter between the Company and Robert Bazemore",
"Epizyme Announces Second Quarter 2015 Financial Results and Provides Corporate Update",
"Epizyme Appoints Robert Bazemore President and Chief Executive Officer"
04/28/2015 8-K Quarterly results
Docs: "Epizyme Announces First Quarter 2015 Financial Results and Provides Corporate Update"
03/12/2015 8-K Quarterly results
Docs: "Epizyme Announces 2014 Financial Results and Provides Corporate Update"
11/06/2014 8-K Quarterly results
Docs: "Epizyme Announces Third Quarter 2014 Financial Results and Provides Corporate Update"
08/13/2014 8-K Quarterly results
Docs: "Epizyme Announces Second Quarter 2014 Financial Results and Provides Corporate Update"
05/13/2014 8-K Quarterly results
Docs: "Epizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update"
02/27/2014 8-K Quarterly results
Docs: "Epizyme Announces 2013 Operating and Financial Results and Provides 2014 Guidance"
10/22/2013 8-K Form 8-K - Current report
07/31/2013 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy